Clinical Trials Details

NRG-GY018 (Endometrial)

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Clinical Trial Categories

  • Cancers and Other Neoplasms